ClinicalTrials.gg
CompletedNCT04524442Updated Jan 24, 2025Results posted

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

A Phase 4 interventional study of arginine/lysine in Gastroenteropancreatic Neuroendocrine Tumors, sponsored by Advanced Accelerator Applications. Completed at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Advanced Accelerator Applications (part of Novartis) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post start of infusion compared to baseline.

Read the detailed description

The study schedule for each patient consisted of a screening period followed by an infusion day with an optional overnight in-clinic stay, and a follow up call 48h post infusion.

Screening Phase:

At screening, patient eligibility was determined according to inclusion and exclusion criteria, with evaluation of patient's vital signs, ECG and laboratory parameters. The duration of screening could be as short as one day but could not exceed 7 days. Patients who showed potassium level > 6.0 mmol/L (> 5.5 mmol/L for Poland only) at screening could have their potassium level corrected and could be re-screened afterwards.

Treatment Phase:

Eligible patients were admitted to the in-clinic unit and dosed with arginine/lysine solution for infusion of 1,000 mL, which was administered intravenously over a period of 4 hours. Before the infusion (at 0 h time point), a set of baseline tests were performed. During and after the infusion, patient condition was monitored for evaluation of any adverse events. Only patients with a potassium level of ≤ 6 mmol/L at screening (> 5.5 mmol/L for Poland only) were allowed to be dosed. Potassium testing on the infusion day was performed at 0h (before the infusion), and at 2h, 4h, 6h, 8h, 12h, and 24h after the start of infusion. Vital signs and ECGs were taken as specified in the assessment schedule. All patients were monitored closely for signs and symptoms of hyperkalemia, e.g. dyspnoea, weakness, numbness, chest pain and cardiac manifestations (conduction abnormalities and cardiac arrhythmias). Other common adverse reactions during arginine/lysine solution administration are nausea and vomiting. Before the start of arginine/lysine solution infusion, an intravenous bolus of an anti-emetic was given. The choice of anti-emetic drugs was at the discretion of the physician.

Follow-up Phase:

All patients were called for a safety follow-up in 48 hours after dosing. Patients were not scheduled to receive repeat dosing with arginine/lysine solution as concomitant medication with Lutathera® within 7 days of the arginine/lysine solution infusion in the study.

02

Conditions studied

  • Gastroenteropancreatic Neuroendocrine Tumors

Keywords

  • GEP-NET
  • Neuroendocrine tumors
  • NETs
  • carcinoid tumors
  • LysaKare
  • arginine/lysine
  • amino acid
  • Peptide Receptor Radionuclide Therapy
  • PRRT
  • Lutathera
  • Lutetium Lu 177 oxodotreotide
  • Lutetium Lu 177 dotatate
03

In context

Gastro-enteropancreatic neuroendocrine tumor

73 studies on the registry are indexed under Gastro-enteropancreatic neuroendocrine tumor; 25 are open to participants now.

This study's enrollment of 42 is below the median of 53 across 49 interventional studies indexed under Gastro-enteropancreatic neuroendocrine tumor.

Browse Gastro-enteropancreatic neuroendocrine tumor studies →

Lead sponsor

Advanced Accelerator Applications is the lead sponsor of 17 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

First submitted after Advanced Accelerator Applications became part of Novartis.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), who are eligible for the treatment with Lutathera as per Lutathera label indication.
  • Patients who have provided a signed form to participate in the study, obtained prior to the start of any protocol related procedures.

Exclusion Criteria:

  • Pre-existing hyperkalemia (>6.0 mmol/L at screening) if not adequately corrected before starting the LysaKare (arginine/lysine) infusion. For Poland only, pre-existing hyperkalemia (> 5.5 mmol/L at screening) if not adequately corrected before starting the LysaKare (arginine/lysine) infusion.
  • Instances when Lutathera is not recommended per the Lutathera Summary of Product Characteristics (SmPC).
  • Pregnancy or lactation, positive pregnancy test at screening or pre-dose based on the for Lutathera.
  • Any significant medical or social condition which may interfere with the subject's ability to comply with the study visit schedule or the study assessments.
  • Patients who have received any agent within the last 30 days.
  • Patients that have received a dose of Lutathera prior to the screening visit or are scheduled for Peptide Receptor Repeat (PRRT) treatment within 7 days of the study infusion of arginine/lysine solution.
  • Other protocol-defined exclusion criteria may apply.

Exclusion Criteria (Poland Only):

  • Pre-existing hyperkalemia (> 5.5 mmol/L at screening) if not adequately corrected before starting the arginine/lysine solution infusion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    GEP-NET

    One dose of arginine/lysine solution administered intravenously over a 4-hour period

    Drug: arginine/lysine

Interventions

  • Drugarginine/lysine

    Drug pages: Arginine · Lysine

    1000 milliliters (mL) administered at a constant rate of 250 mL per hour

    Also known as: LysaKare

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Serum Potassium Levels Over 24 Hours

    Serum potassium levels at each collection time point will be measured at local laboratories of study sites using validated methods. The potassium concentration results will be summarized descriptively and will include mean change, maximum change, time to the maximum change, and the overall dynamics of the potassium concentration curve during and after the arginine/lysine infusion.

    Time frame: Day 0/Infusion Day (Hour 0, Hour 2, Hour 4, Hour 6, Hour 8, Hour 12, Hour 24)

Secondary outcomes

  1. Percentage of Participants With Treatment Adverse Events (AEs) & Serious Adverse Events (SAEs)

    Safety measured by the percentage of participants with treatment emergent adverse events (starting from the signing of the ICF until the end of the follow-up call (48 hours after infusion).

    Time frame: Day 0/Infusion Day up to 48 hours post infusion

  2. Number of Participants With Notable Changes in Vital Signs

    Safety measured by the notable post-baseline changes in vital signs: (systolic blood pressure, diastolic blood pressure, pulse rate \& weight) compared to baseline.

    Time frame: Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)

  3. Number of Participants With Notable Changes in Electrocardiogram (ECG)

    Safety measured by the notable post-baseline changes in ECG values compared to baseline PR, QRS, QT, QTcF, and RR intervals were obtained from 12-lead ECGs for each subject during the study

    Time frame: Day 0/Infusion Day (0, 4, 8 and 24 hours)

  4. Number of Participants With Notable Changes in Hematology Parameters

    Safety measured by the notable post-baseline changes in Hematology parameters compared to baseline as represented by Shift tables based on common toxicity criteria (CTC) grades. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline.

    Time frame: Day 0/Infusion Day (0 and 24 hours)

  5. Number of Participants With Notable Changes in Chemistry Parameters

    Safety measured by the notable post-baseline changes in Chemistry parameters compared to baseline. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline. Key shifts were in the following parameters: creatinine, lactate dehydrogenase and creatinine clearance.

    Time frame: Day 0/Infusion Day (0 and 24 hours)

  6. Number of Participants With Notable Changes in Electrolyte Parameters

    Safety measured by the notable post-baseline changes in Electrolyte parameters compared to baseline. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline.

    Time frame: Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)

  7. Mean Change From Baseline in Blood Gas Parameter, pH, Over 24 Hours

    Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: pH.

    Time frame: Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)

  8. Mean Change From Baseline in Blood Gas Parameter, Lactic Acid, Over 24 Hours

    Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: Lactic Acid

    Time frame: Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)

  9. Mean Change From Baseline in Blood Gas Parameter, Partial Pressure Carbon Dioxide, Over 24 Hours

    Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: Partial Pressure Carbon Dioxide.

    Time frame: Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)

07

Results

Posted Jan 24, 2025

Participant flow

A total of 42 participants were enrolled in 7 centers in 4 countries.

Participant flow — Overall Study
MilestoneGEP-NET
Started42
Treated41
Not treated1
Post-treatment follow-up phase (48 hrs post-infusion)40
Completed41
Not completed1
Withdrew: Subject decision1

Outcome measures

PrimaryMean Change From Baseline in Serum Potassium Levels Over 24 Hours

Serum potassium levels at each collection time point will be measured at local laboratories of study sites using validated methods. The potassium concentration results will be summarized descriptively and will include mean change, maximum change, time to the maximum change, and the overall dynamics of the potassium concentration curve during and after the arginine/lysine infusion.

Time frame:
Day 0/Infusion Day (Hour 0, Hour 2, Hour 4, Hour 6, Hour 8, Hour 12, Hour 24)
Reported as:
Mean · mmol/L
Mean Change From Baseline in Serum Potassium Levels Over 24 Hours
mmol/LGEP-NET
Pre-dose (hour 0)4.3 ± 0.397
Change from Baseline (BL) to Hour 20.25 ± 0.452
Change from Baseline (BL) to Hour 40.60 ± 0.666
Change from Baseline (BL) to Hour 60.49 ± 0.602
Change from Baseline (BL) to Hour 80.38 ± 0.487
Change from Baseline (BL) to Hour 120.24 ± 0.557
Change from Baseline (BL) to Hour 240.07 ± 0.396
SecondaryPercentage of Participants With Treatment Adverse Events (AEs) & Serious Adverse Events (SAEs)

Safety measured by the percentage of participants with treatment emergent adverse events (starting from the signing of the ICF until the end of the follow-up call (48 hours after infusion).

Time frame:
Day 0/Infusion Day up to 48 hours post infusion
Reported as:
Count of participants · Participants
Percentage of Participants With Treatment Adverse Events (AEs) & Serious Adverse Events (SAEs)
ParticipantsGEP-NET
Adverse Event (AEs)11
Treatment-related AEs6
Serious Adverse Events (SAEs)0
Fatal SAEs0
AEs leading to discontinuation0
AEs leading to Interrruption0
AEs requiring additional therapy5
Treatment related AEs req. additional therapy3
SecondaryNumber of Participants With Notable Changes in Vital Signs

Safety measured by the notable post-baseline changes in vital signs: (systolic blood pressure, diastolic blood pressure, pulse rate \& weight) compared to baseline.

Time frame:
Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)
Reported as:
Number · Participants
Number of Participants With Notable Changes in Vital Signs
ParticipantsGEP-NET
Systolic blood pressure (mmHg): ≥180 with increase from baseline of ≥200
Systolic blood pressure (mmHg): ≤ 90 with decrease from baseline of ≥200
Diastolic blood pressure (mmHg): ≥105 with increase from baseline of ≥150
Diastolic blood pressure (mmHg): ≤ 50 with decrease from baseline of ≥150
Pulse rate (bpm): ≥100 with increase from baseline of >25%0
Pulse rate (bpm): ≤ 50 with decrease from baseline of > 25%0
Weight (kg): increase ≥10% from Baseline0
Weight (kg): decrease > 10% from Baseline0
SecondaryNumber of Participants With Notable Changes in Electrocardiogram (ECG)

Safety measured by the notable post-baseline changes in ECG values compared to baseline PR, QRS, QT, QTcF, and RR intervals were obtained from 12-lead ECGs for each subject during the study

Time frame:
Day 0/Infusion Day (0, 4, 8 and 24 hours)
Reported as:
Count of participants · Participants
Number of Participants With Notable Changes in Electrocardiogram (ECG)
ParticipantsGEP-NET
QTcF (ms): Increase >30 to ≤ 60 ms7
QTcF (ms): Increase >60 ms0
QTcF (ms): New >450 to ≤ 480 ms7
QTcF (ms): New >480 to ≤ 500 ms0
QTcF (ms); New >500 ms0
QT (ms): Increase >30 to ≤ 60 ms9
QT (ms): Increase >60 ms2
QT (ms): New >450 to ≤ 480 ms6
QT (ms): New >480 to ≤ 500 ms1
QT (ms): New >500 ms0
PR (ms): Increase >25% and PR >200 ms1
PR (ms): New PR >200 ms6
QRS (ms): Increase >25% and QRS >120 ms2
QRS (ms): New QRS >120 ms2
HR (bpm): Increase >25% and HR >100 bpm0
HR (bpm): Decrease >25% and HR <50 bpm0
SecondaryNumber of Participants With Notable Changes in Hematology Parameters

Safety measured by the notable post-baseline changes in Hematology parameters compared to baseline as represented by Shift tables based on common toxicity criteria (CTC) grades. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline.

Time frame:
Day 0/Infusion Day (0 and 24 hours)
Reported as:
Count of participants · Participants
Number of Participants With Notable Changes in Hematology Parameters
ParticipantsGEP-NET
Number of Participants With Notable Changes in Hematology Parameters0
SecondaryNumber of Participants With Notable Changes in Chemistry Parameters

Safety measured by the notable post-baseline changes in Chemistry parameters compared to baseline. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline. Key shifts were in the following parameters: creatinine, lactate dehydrogenase and creatinine clearance.

Time frame:
Day 0/Infusion Day (0 and 24 hours)
Reported as:
Count of participants · Participants
Number of Participants With Notable Changes in Chemistry Parameters
ParticipantsGEP-NET
Creatinine (increase)4
Lactate dehydrogenase (increase)3
Creatinine clearance (decrease)4
SecondaryNumber of Participants With Notable Changes in Electrolyte Parameters

Safety measured by the notable post-baseline changes in Electrolyte parameters compared to baseline. Each participant was counted only for the worst grade observed post-baseline. Notable change is the shift to higher grades from baseline.

Time frame:
Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)
Reported as:
Count of participants · Participants
Number of Participants With Notable Changes in Electrolyte Parameters
ParticipantsGEP-NET
For Potassium (increase)7
For sodium (decrease)12
SecondaryMean Change From Baseline in Blood Gas Parameter, pH, Over 24 Hours

Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: pH.

Time frame:
Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)
Reported as:
Mean · unitless
Mean Change From Baseline in Blood Gas Parameter, pH, Over 24 Hours
unitlessGEP-NET
Day 0/Infusion Day (Pre-dose) (hour 0)7.35 ± 0.046
Change from Baseline (BL) to Hour 2-0.03 ± 0.046
Change from Baseline (BL) to Hour 4-0.06 ± 0.055
Change from Baseline (BL) to Hour 6-0.05 ± 0.051
Change from Baseline (BL) to Hour 8-0.05 ± 0.056
Change from Baseline (BL) to Hour 12-0.03 ± 0.054
Change from Baseline (BL) to Hour 24-0.04 ± 0.051
SecondaryMean Change From Baseline in Blood Gas Parameter, Lactic Acid, Over 24 Hours

Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: Lactic Acid

Time frame:
Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)
Reported as:
Mean · mmol/L
Mean Change From Baseline in Blood Gas Parameter, Lactic Acid, Over 24 Hours
mmol/LGEP-NET
Day 0/Infusion Day (Pre-dose) (hour 0)1.40 ± 0.604
Change from Baseline (BL) to Hour 2-0.07 ± 0.671
Change from Baseline (BL) to Hour 4-0.23 ± 0.523
Change from Baseline (BL) to Hour 6-0.26 ± 0.546
Change from Baseline (BL) to Hour 8-0.19 ± 0.465
Change from Baseline (BL) to Hour 12-0.21 ± 0.657
Change from Baseline (BL) to Hour 24-0.16 ± 0.650
SecondaryMean Change From Baseline in Blood Gas Parameter, Partial Pressure Carbon Dioxide, Over 24 Hours

Safety measured by the mean changes in blood gas compared to baseline. Blood gas parameter: Partial Pressure Carbon Dioxide.

Time frame:
Day 0/Infusion Day (0, 2, 4, 6, 8, 12 and 24 hours)
Reported as:
Mean · mmHg
Mean Change From Baseline in Blood Gas Parameter, Partial Pressure Carbon Dioxide, Over 24 Hours
mmHgGEP-NET
Day 0/Infusion Day (Pre-dose) (hour 0)50.53 ± 8.712
Change from Baseline (BL) to Hour 2-1.08 ± 6.670
Change from Baseline (BL) to Hour 4-2.44 ± 8.717
Change from Baseline (BL) to Hour 6-4.90 ± 8.507
Change from Baseline (BL) to Hour 8-4.87 ± 8.399
Change from Baseline (BL) to Hour 12-5.71 ± 8.002
Change from Baseline (BL) to Hour 24-2.54 ± 8.242

Adverse events

Collected over Adverse Events (AEs) were collected from the administration of the study treatment up to 48 hours in addition to the infusion time, an average of 52 hours total.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants0/41 (0%)0/41 (0%)11/41 (26.8%)
Most frequent other events
Most frequent other events
EventAll Participants
HyperkalaemiaMetabolism and nutrition disorders5/41
NauseaGastrointestinal disorders2/41
Abdominal painGastrointestinal disorders1/41
ProctalgiaGastrointestinal disorders1/41
VomitingGastrointestinal disorders1/41
FatigueGeneral disorders1/41
ContusionInjury, poisoning and procedural complications1/41
DizzinessNervous system disorders1/41
HeadacheNervous system disorders1/41
Respiratory acidosisRespiratory, thoracic and mediastinal disorders1/41

Baseline characteristics

Safety Set: The Safety Set (SAF) comprises all subjects who received any administration of the LysaKare infusion in the study.

Age, Continuous
Age, Continuous(Years)GEP-NET
Mean57.7 ± 9.46
Sex: Female, Male
Sex: Female, Male(Participants)GEP-NET
Female19
Male22
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GEP-NET
White38
Black or African American3
08

Study locations

7 sites
  • Istituto Europeo di Oncologia
    Milan, MI 20141, Italy
  • Erasmus University Medical Center
    Rotterdam, GD 3015, Netherlands
  • Gammed-Centrum Diagnostyczno-Lecznicze
    Warsaw, 02-351, Poland
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B15 2GW, United Kingdom
  • University Hospitals Coventry & Warwickshire NHS Trust
    Coventry, CV2 2DX, United Kingdom
  • Royal Surrey Country Hospital
    Guildford, GU2 7XX, United Kingdom
  • Liverpool Royal Hospital
    Liverpool, L7 8YA, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Nov 2023, 33 months.

Results were first posted in Jan 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2020
First posted
Aug 24, 2020
StartActual
Jan 25, 2021
Primary completionActual
Nov 18, 2023
CompletionActual
Nov 18, 2023
Results first posted
Jan 24, 2025
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04524442
Responsible party
Sponsor
First posted
Aug 24, 2020
Start date
Jan 25, 2021
Primary completion
Nov 18, 2023
Completion
Nov 18, 2023
Results posted
Jan 24, 2025
Last update
Jan 24, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Arginine · Lysine

Start the discussion